|Bid||12.04 x 800|
|Ask||23.00 x 1400|
|Day's Range||21.83 - 22.67|
|52 Week Range||20.01 - 56.59|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This morning, we issued a press release announcing our first-quarter 2021 financial results and business update. On today's call, Chris Martin, chief executive officer; Jennifer Herron, our chief commercial officer; Jay Feingold, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent business highlights and review our first-quarter 2021 financial results before opening the call for questions.
ADC Therapeutics SA (NYSE: ADCT) has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two prior lines of therapy. Following a priority review in November with a review date of May 21, Zylonta’s accelerated nod comes a month ahead of schedule. The company will have to prove its clinical benefit in a confirmatory study to maintain its marketing approval. The approval comes just under a year after ADC went public, raising 3 million. The FDA endorsed the drug based on data from a Phase 2 trial, LOTIS 2. The drug turned in an overall response rate of 48.3%, and, for those who responded, the median duration of response was 10.3 months. More than 24% of patients experienced a complete response. Price Action: ADCT shares are up 5.72% at $24.58 in the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaRoche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive OpinionBristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
This morning, we issued a press release announcing our fourth quarter and year-end 2020 financial results and business update. On today's call, Chris Martin, chief executive officer; Jay Feingold, chief medical officer; and Jen Creel, chief financial officer, will discuss recent business highlights and review our fourth quarter and year-end 2020 financial results. In addition, Jennifer Herron, our chief commercial officer, will be available for questions.